These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10783488)

  • 1. Resistance of cancer cells to immune recognition and killing.
    Lipinski B; Egyud LG
    Med Hypotheses; 2000 Mar; 54(3):456-60. PubMed ID: 10783488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human natural killer cells: a comprehensive review.
    Sinkovics JG; Horvath JC
    Int J Oncol; 2005 Jul; 27(1):5-47. PubMed ID: 15942642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of HLA expression in human tumor tissues.
    Cabrera T; López-Nevot MA; Gaforio JJ; Ruiz-Cabello F; Garrido F
    Cancer Immunol Immunother; 2003 Jan; 52(1):1-9. PubMed ID: 12536234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene transfer approaches in cancer immunotherapy.
    Larin SS; Georgiev GP; Kiselev SL
    Gene Ther; 2004 Oct; 11 Suppl 1():S18-25. PubMed ID: 15454953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune selection in murine tumors. Ph.d thesis.
    Svane IM; Engel AM
    APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo antitumor activity of methotrexate conjugated to human serum albumin in human cancer cells.
    Wosikowski K; Biedermann E; Rattel B; Breiter N; Jank P; Löser R; Jansen G; Peters GJ
    Clin Cancer Res; 2003 May; 9(5):1917-26. PubMed ID: 12738750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of thermal stress on tumor antigenicity and recognition by immune effector cells.
    Milani V; Noessner E
    Cancer Immunol Immunother; 2006 Mar; 55(3):312-9. PubMed ID: 16151807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin clot adhesion to dentin conditioned with protein constructs: an in vitro proof-of-principle study.
    Baker DL; Stanley Pavlow SA; Wikesjö UM
    J Clin Periodontol; 2005 Jun; 32(6):561-6. PubMed ID: 15882212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experimental evidence for killing the resistant cells and raising the efficacy and decreasing the toxicity of cytostatics and irradiation by mixtures of the agents of the passive antitumor defense system in the case of various tumor and normal cell lines in vitro.
    Kulcsár G
    Cancer Biother Radiopharm; 2009 Feb; 24(1):67-80. PubMed ID: 19243249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes.
    Garnett CT; Palena C; Chakraborty M; Tsang KY; Schlom J; Hodge JW
    Cancer Res; 2004 Nov; 64(21):7985-94. PubMed ID: 15520206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-host immune interactions and dendritic cell dysfunction.
    Yang L; Carbone DP
    Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
    Frankel A; Man S; Elliott P; Adams J; Kerbel RS
    Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of fibrin formation and dissolution in the pathogenesis and treatment of cancer.
    Egyud LG; Lipinski B
    Med Hypotheses; 1991 Dec; 36(4):336-40. PubMed ID: 1687326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells.
    Poggi A; Zocchi MR
    Arch Immunol Ther Exp (Warsz); 2006; 54(5):323-33. PubMed ID: 17031467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?
    Rouas-Freiss N; Moreau P; Ferrone S; Carosella ED
    Cancer Res; 2005 Nov; 65(22):10139-44. PubMed ID: 16287995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
    Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
    Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three-dimensional culture system as a model for studying cancer cell invasion capacity and anticancer drug sensitivity.
    Doillon CJ; Gagnon E; Paradis R; Koutsilieris M
    Anticancer Res; 2004; 24(4):2169-77. PubMed ID: 15330157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for the treatment of cancer with sodium selenite.
    Lipinski B
    Med Hypotheses; 2005; 64(4):806-10. PubMed ID: 15694701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunologic consequences of laparoscopy in oncology.
    Carter JJ; Whelan RL
    Surg Oncol Clin N Am; 2001 Jul; 10(3):655-77. PubMed ID: 11685934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.